ReviewWorld journal of gastroenterology2016
Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The consistencies and inconsistencies between distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study.Journal of gastrointestinal oncology · 2026Article
- Pancreatic Cancer Cells Induce MicroRNA Deregulation in Platelets.International journal of molecular sciences · 2022Article
- Article
- Use of liquid biopsies in gastrointestinal cancers.World journal of gastrointestinal oncology · 2021Article
- The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms.Journal of clinical medicine · 2021Review
- Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer.Translational oncology · 2021Review
- Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer.Cancers · 2020Article
- Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?International journal of molecular sciences · 2020Review
- Review
- Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model.Journal of toxicologic pathology · 2019Article
- Review
- Synthesis and assessment of ZD2-(American journal of nuclear medicine and molecular imaging · 2019Article
- The dawn of the liquid biopsy in the fight against cancer.Oncotarget · 2018Review
- The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.Canadian journal of gastroenterology & hepatology · 2018Review
- Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.Oncotarget · 2017Article
- Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.World journal of gastrointestinal oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a disease that carries a poor prognosis. Accurate tissue diagnosis is required. Tumours contain a high content of stromal tissue and therefore biopsies may be inconclusive. Circulating tumour cells (CTCs) have been investigated as a potential "liquid biopsy" in several malignancies and have proven to be of prognostic value in breast, prostate and colorectal cancers. They have been detected in patients with localised and metastatic pancreatic cancer with sensitivities ranging from 38%-100% using a variety of platforms. Circulating tumour DNA (ctDNA) has also been detected in pancreas cancer with a sensitivity ranging from 26%-100% in studies across different platforms and using different genetic markers. However, there is no clear consensus on which platform is the most effective for detection, nor which genetic markers are the most useful to use. Potential roles of liquid biopsies include diagnosis, screening, guiding therapies and prognosis. The presence of CTCs or ctDNA has been shown to be of prognostic value both at diagnosis and after treatment in patients with pancreatic cancer. However, more prospective studies are required before this promising technology is ready for adoption into routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.